This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Akili Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Akili has been growing earnings at an average annual rate of 7.6%, while the Healthcare Services industry saw earnings growing at 13.3% annually. Revenues have been growing at an average rate of 426.5% per year.

Anahtar bilgiler

7.6%

Kazanç büyüme oranı

48.1%

EPS büyüme oranı

Healthcare Services Sektör Büyümesi	12.9%
Gelir büyüme oranı	426.5%
Özkaynak getirisi	-96.7%
Net Marj	-2,492.0%
Son Kazanç Güncellemesi	31 Mar 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Akili nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

BMV:AKLI * Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
31 Mar 24	2	-49	39	18
31 Dec 23	2	-59	45	20
30 Sep 23	1	-65	52	23
30 Jun 23	0	2	55	26
31 Mar 23	0	-14	59	29
31 Dec 22	0	-19	62	29
30 Sep 22	0	-26	61	27
30 Jun 22	0	-99	58	24
31 Mar 22	0	-144	53	21
31 Dec 21	1	-127	43	18
30 Sep 21	0	-111	32	17
31 Dec 20	4	-26	14	15
31 Dec 19	20	-21	19	21

Kaliteli Kazançlar: AKLI * is currently unprofitable.

Büyüyen Kar Marjı: AKLI * is currently unprofitable.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: AKLI * is unprofitable, but has reduced losses over the past 5 years at a rate of 7.6% per year.

Büyüme Hızlandırma: Unable to compare AKLI *'s earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: AKLI * is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (8%).

Özkaynak Getirisi

Yüksek ROE: AKLI * has a negative Return on Equity (-96.69%), as it is currently unprofitable.

This company listing is no longer active

Akili Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Full year 2023 earnings released: US$0.76 loss per share (vs US$0.64 loss in FY 2022)

Akili, Inc. to Report Q4, 2023 Results on Feb 29, 2024

First quarter 2023 earnings released: US$0.27 loss per share (vs US$17.96 loss in 1Q 2022)

Recent updates

Akili, Inc.(NasdaqCM:AKLI) dropped from NASDAQ Composite Index

Akili to Delist from Nasdaq

Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with AdHD Through a Video Game

Virtual Therapeutics Corp. entered into an agreement to acquire Akili, Inc. (NasdaqCM:AKLI) for $35 million.

Virtual Therapeutics Corp. entered into an agreement to acquire Akili, Inc. (NasdaqCM:AKLI) for $35 million.

Akili, Inc. to Reduce Workforce

Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product

Akili, Inc. Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC

Full year 2023 earnings released: US$0.76 loss per share (vs US$0.64 loss in FY 2022)

High number of new and inexperienced directors

Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx®? for Pediatric Adhd Patients in Japan

Akili, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024

Akili Receives Non-Compliance Notice from Nasdaq

Akili, Inc. Announces Kenneth Ehlert Resigns as A Member of the Board of Director, Member of the Audit Committee and Nominating and Corporate Governance Committee of the Board

Akili, Inc. Receives Authorization from the U.S. Food and Drug Administration

Akili Receives Non-Compliance Notice from Nasdaq

Akili, Inc. Releases Results from A New Study Examining the Way in Which Adhd Impacting the U.S. Workforce

Akili, Inc. Announces CEO Changes

Akili Releases EndeavorOTC on Android Devices, Expanding Treatment Access for Millions of Adults with Adhd

High number of new and inexperienced directors

Akili Releases EndeavorOTC Video Game Treatment to Improve Attention in Adults with Adad

Akili, Inc. to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with Adolescents At 2023

First quarter 2023 earnings released: US$0.27 loss per share (vs US$17.96 loss in 1Q 2022)

High number of new and inexperienced directors

High number of new and inexperienced directors

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin